X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares traded 3.10% higher at $1.16 on Wall Street last session.
XFOR stock price is now 3.23% away from the 50-day moving average and 9.68% away from the 200-day moving average. The market capitalization of the company currently stands at $195.65M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $3 to $1, B. Riley Securities Downgraded its rating from Buy to Neutral for X4 Pharmaceuticals Inc (NASDAQ: XFOR). , while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Mostafa Adam S., Chief Financial Officer sold 52,500 shares of the company’s stock on Mar 11 ’24. The stock was sold for $46,347 at an average price of $0.88. Upon completion of the transaction, the Chief Financial Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’24, President and CEO Ragan Paula sold 49,678 shares of the business’s stock. A total of $43,856 was realized by selling the stock at an average price of $0.88. This leaves the insider owning 765,068 shares of the company worth $0.89 million. A total of 27.30% of the company’s stock is owned by insiders.
During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.57 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 1.14, a current ratio of 5.34, and a quick ratio of 5.34.
According to the Biotechnology Company, earnings per share came in at -0.16, beating analysts’ expectations of -0.22 by 0.06. This compares to $0.03 EPS in the same period last year. The company reported revenue of $25.2 million for the quarter, compared to $25.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.48 percent.
